Skip to main content
S&P 5007,659.44-1.09%DOW52,002.41-0.34%NASDAQ26,140.03-2.14%BTC$81,442.00-0.92%ETH$2,417.14-0.81%GOLD$4,186.70+0.40%OIL$99.04+2.63%
Smart Investors Daily
SID Premium
AB

NASDAQ · ABSI

Absci Corporation

Healthcare · Biotechnology

$8.25

Down-$0.63 (-7.09%)

Updated Oct 18, 2026, 3:19 AM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
412.02M
P/E ratio
-3.44
Dividend yield
0.00%
52-week range
$2.24 – $12.06
Volume
3.55M
Avg. volume
3.49M

Price performance · ABSI

ABSI price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 16, 2026

ABSI closed at $8.25 after 20 trading sessions, down 15.99% for the selected period.

Last close
$8.25
Period change
-15.99%
Period low
$8.25
Period high
$11.53
Daily close
View OHLC price history
ABSI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 16, 2026$8.93$8.95$8.12$8.253.55M
Oct 15, 2026$8.43$8.945$8.23$8.883.4M
Oct 14, 2026$8.88$9.12$8.62$8.743.56M
Oct 13, 2026$9.445$9.66$9.00$9.103.05M
Oct 12, 2026$10.065$10.09$9.43$9.672.86M
Oct 9, 2026$9.20$10.3902$8.93$10.164.25M
Oct 8, 2026$9.04$9.27$8.81$8.944.68M
Oct 7, 2026$10.00$10.22$9.1201$9.225.85M
Oct 6, 2026$11.77$11.89$10.21$10.275.88M
Oct 5, 2026$11.105$11.80$10.87$11.534.29M
Oct 2, 2026$11.14$11.345$10.83$11.073.38M
Oct 1, 2026$10.80$11.27$10.552$10.754.61M
Sep 30, 2026$10.355$10.99$10.04$10.775.43M
Sep 29, 2026$9.59$10.18$9.485$10.143.42M
Sep 28, 2026$9.57$9.6694$9.25$9.493.25M
Sep 25, 2026$10.49$10.50$9.68$9.743.21M
Sep 24, 2026$9.55$10.39$9.30$10.3453.39M
Sep 23, 2026$10.51$10.62$9.47$9.7454.72M
Sep 22, 2026$10.00$11.255$9.75$10.718.37M
Sep 21, 2026$10.06$10.15$9.50$9.824.56M

Latest ABSI news

The latest Smart Investors Daily articles mentioning ABSI.

Stock researchCompany · Overview

ABSI research

Overview

Company profile and research snapshot.

Company profile

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$6.00
Implied upside
—
Analysts
15
ABSI recent ratings
DateFirmRatingTarget
Oct 16, 2026KeybancOverweight—
Oct 12, 2026JP MorganOverweight—
Oct 12, 2026HC Wainwright & Co.Buy—
Sep 23, 2026NeedhamBuy—
Sep 9, 2026LifeSci CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 13, 2026

Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026

VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2026 before market open on Thursday, November 12, 2026. Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time)

Yahoo · Oct 7, 2026

Absci (ABSI) Stock Dropped, So What Is Behind The Latest Attention?

Absci (ABSI) is back in focus after management outlined fresh details for its planned global Phase 2 STORYLINE trial of ABS-201 in endometriosis, giving investors a clearer read on this pipeline project. After the ABS-201 STORYLINE update, Absci’s share price has been volatile, with the stock down 10.22% over the past day and 14.39% over the past week, yet still posting a 30 day share price return of 4.54% and a very large 3 year total shareholder return. This suggests that long term momentum...

Yahoo · Sep 24, 2026

Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced additional details for the company’s planned global, multi-center

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By